Combination therapy for localized pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of drugs for people with localized pancreatic cancer who have already completed 8 cycles of modified FOLFIRINOX chemotherapy before surgery. The goal is to see if adding these drugs after chemo and radiation helps improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with pancreatic ductal adenocarcinoma (a type of pancreatic cancer).
- You must have completed 8 cycles of a chemotherapy called modified FOLFIRINOX before surgery.
- Your cancer must be considered removable by surgery, and you must be eligible for a type of radiation called SBRT.
- You must be 18 years or older and have a good performance status (able to do daily activities without significant help).
- You cannot have received prior immunotherapy drugs or other cancer treatments (except modified FOLFIRINOX).
- You cannot have active autoimmune disease, active infections like HIV or hepatitis, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of high-dose radiation (SBRT) and an immunotherapy drug called zimberelimab for people with locally advanced pancreatic cancer that can't be surgically removed. The goal is to see if the combination shrinks tumors or slows their growth better than standard care.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a new combination of drugs with radiation therapy for people with locally advanced pancreatic cancer that cannot be removed with surgery. The treatment aims to shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
This study tests a new treatment approach for pancreatic cancer that is on the edge of being removable with surgery. It combines radiation therapy with chemotherapy and an immunotherapy drug (a PD-1 inhibitor) plus a thymalfasin (a medication that helps regulate the immune system) to see if this combination can help shrink the tumor before surgery.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.